Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections

@inproceedings{Stewart2017RealWorldEW,
  title={Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections},
  author={Cassie L. Stewart and Michelle S. Turner and Jeremy J. Frens and Cynthia B. Snider and Jordan R. Smith},
  booktitle={Infectious diseases and therapy},
  year={2017}
}
INTRODUCTION Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited. METHODS We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
Other indications for oritavancin use included methicillin - resistant S. aureus ( MRSA ) bursitis ( n = 1 , 10% ) , group B streptococcal bacteremia with native tricuspid valve infective endocarditis ( n = 1 , 10% ) , coagulase - negative staphylococcal bacteremia ( n = 1 , 10% ) , MSSA deep tissue infection ( n = 1 , 10% ) , and enterococcal bacteremia ( n = 1 , 10% ) .
All Topics